Theleme Partners LLP: MODERNA INC (MRNA): Quarterly 13F Position History
As of Q1 2026, Theleme Partners LLP reported 8,048,245 shares of MODERNA INC (MRNA), worth $408.9M and representing 27.2% of its 13F equity book. Quarter-over-quarter share count change: 33,565 (-0.4%) . The position first appeared in Q4 2018 and has been disclosed across 30 13F-HR filings in Pactolio's tracked window.
- 8,048,245Shares Held (Latest Filing)
- $408.9MReported Market Value (Latest Filing)
- 27.2%Portfolio Weight (% of 13F Equity Book)
- 33,565Quarter-over-Quarter Share Change
- +$170.5MQuarter-over-Quarter Value Change
- 8,930,919Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 30 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,048,245 | 33,565 | -0.4% | $408.9M | 27.2% | $50.8 |
| Q4 2025 | 8,081,810 | +13,000 | +0.2% | $238.3M | 15.5% | $29.5 |
| Q3 2025 | 8,068,810 | +200,000 | +2.5% | $208.4M | 13.3% | $25.8 |
| Q2 2025 | 7,868,810 | +626,420 | +8.6% | $217.1M | 13.2% | $27.6 |
| Q1 2025 | 7,242,390 | 64,471 | -0.9% | $205.3M | 16.1% | $28.4 |
| Q4 2024 | 7,306,861 | +80,000 | +1.1% | $303.8M | 20.4% | $41.6 |
| Q3 2024 | 7,226,861 | 0 | — | $483.0M | 28.5% | $66.8 |
| Q2 2024 | 7,226,861 | 94,936 | -1.3% | $858.2M | 42.7% | $118.8 |
| Q1 2024 | 7,321,797 | 27,659 | -0.4% | $780.2M | 42.9% | $106.6 |
| Q4 2023 | 7,349,456 | +451,844 | +6.6% | $730.9M | 38.5% | $99.5 |
| Q3 2023 | 6,897,612 | +651,113 | +10.4% | $712.5M | 35.8% | $103.3 |
| Q2 2023 | 6,246,499 | +134,065 | +2.2% | $758.9M | 34.4% | $121.5 |
| Q1 2023 | 6,112,434 | +253,576 | +4.3% | $938.7M | 40.4% | $153.6 |
| Q4 2022 | 5,858,858 | 145,548 | -2.4% | $1.1B | 40.5% | $179.6 |
| Q3 2022 | 6,004,406 | 350,000 | -5.5% | $710.0M | 34.6% | $118.3 |
| Q2 2022 | 6,354,406 | +17,466 | +0.3% | $907.7M | 36.4% | $142.8 |
| Q1 2022 | 6,336,940 | +1,314,766 | +26.2% | $1.1B | 34.9% | $172.3 |
| Q4 2021 | 5,022,174 | +1,065,100 | +26.9% | $1.3B | 21.3% | $254.0 |
| Q3 2021 | 3,957,074 | 2,114,982 | -34.8% | $1.5B | 43.5% | $384.9 |
| Q2 2021 | 6,072,056 | 230,000 | -3.6% | $1.4B | 41.7% | $235.0 |
| Q1 2021 | 6,302,056 | +958,358 | +17.9% | $825.3M | 27.6% | $130.9 |
| Q4 2020 | 5,343,698 | 2,309,280 | -30.2% | $558.3M | 19.4% | $104.5 |
| Q3 2020 | 7,652,978 | 893,941 | -10.5% | $541.4M | 26.5% | $70.8 |
| Q2 2020 | 8,546,919 | 384,000 | -4.3% | $548.8M | 27.8% | $64.2 |
| Q1 2020 | 8,930,919 | +2,490,645 | +38.7% | $267.5M | 21.9% | $29.9 |
| Q4 2019 | 6,440,274 | +827,829 | +14.7% | $126.0M | 7.1% | $19.6 |
| Q3 2019 | 5,612,445 | +1,757,647 | +45.6% | $89.3M | 4.7% | $15.9 |
| Q2 2019 | 3,854,798 | +2,222,285 | +136.1% | $56.4M | 3.4% | $14.6 |
| Q1 2019 | 1,632,513 | +502,513 | +44.5% | $33.2M | 2.0% | $20.4 |
| Q4 2018 | 1,130,000 | — | — | $17.3M | 1.1% | $15.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Theleme Partners LLP first disclose a MRNA position in 13F-HR filings?
Theleme Partners LLP first reported MODERNA INC (MRNA) on its 13F-HR filing for the period ending 2018-12-31 (Q4 2018). The position has appeared on 30 reported quarters within Pactolio's tracked window.
What was Theleme Partners LLP's most recent quarter-over-quarter share-count change in MRNA?
Between Q4 2025 and Q1 2026, Theleme Partners LLP reduced its MRNA position by 33,565 shares (-0.4%), leaving 8,048,245 shares at a market value of $408.9M.
Does the implied price-per-share represent Theleme Partners LLP's cost basis in MRNA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.